二甲双胍联合胰岛素治疗孕早期已有2型糖尿病或妊娠期糖尿病:MOMPOD随机临床试验
这项在美国17个中心开展的随机临床试验纳入孕前2型糖尿病或孕23周前诊断糖尿病的孕妇,在胰岛素基础上加用二甲双胍1000 mg每日两次或安慰剂。主要复合不良新生儿结局在二甲双胍组280例(71%)与安慰剂组292例(74%)间无显著差异(校正OR 0.86,95%CI 0.63-1.19)。二甲双胍组小于胎龄儿 odds 降低(校正OR 0.63,95%CI 0.46-0.86),需进一步研究。
要点
- 二甲双胍联合胰岛素未降低复合不良新生儿结局(校正OR 0.86,95%CI 0.63-1.19)。
- 二甲双胍组大于胎龄儿 odds 低于安慰剂组(校正OR 0.63,95%CI 0.46-0.86)。
- 研究因主要结局无显著差异的无效性在75%入组时终止。
核心结论
- 在孕前2型糖尿病或孕早期诊断的妊娠期糖尿病患者中,胰岛素加用二甲双胍未降低复合不良新生儿结局。
- 加用二甲双胍后观察到大于胎龄儿 odds 降低,其效应需进一步研究。
研究设计与样本
- 美国17个中心开展的随机临床试验,2019年4月至2021年11月入组18至45岁孕前2型糖尿病或孕23周前诊断糖尿病的孕妇。
- 831例随机分组,794例至少接受1剂研究药物并纳入主要分析(安慰剂组397例,二甲双胍组397例)。
- 干预为入组时(孕11周至<23周)至分娩期间口服二甲双胍1000 mg或安慰剂,每日两次。
- 随访于2022年5月完成。
主要发现
- 主要复合不良新生儿结局(围产期死亡、早产、大于或小于胎龄儿、需光疗的高胆红素血症)在二甲双胍组280例(71%) vs 安慰剂组292例(74%),校正OR 0.86(95%CI 0.63-1.19)。
- 两组主要结局中最常见事件为早产、新生儿低血糖和大于胎龄儿分娩。
- 研究因主要结局无显著差异的无效性在75%入组时终止。
- 预设次要结局和亚组分析在两组间相似。
- 二甲双胍暴露新生儿大于胎龄儿 odds 低于安慰剂组(校正OR 0.63,95%CI 0.46-0.86)。
关键数值与推荐
- 主要复合不良新生儿结局:二甲双胍组280例(71%) vs 安慰剂组292例(74%),校正OR 0.86(95%CI 0.63-1.19)。
- 大于胎龄儿:二甲双胍组校正OR 0.63(95%CI 0.46-0.86),低于安慰剂组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因主要结局无显著差异的无效性在75%入组时终止。
- 加用二甲双胍后大于胎龄儿 odds 降低的效应需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Insulin is recommended for pregnant persons with preexisting type 2 diabetes or diabetes diagnosed early in pregnancy. The addition of metformin to insulin may improve neonatal outcomes. OBJECTIVE: To estimate the effect of metformin added to insulin for preexisting type 2 or diabetes diagnosed early in pregnancy on a composite adverse neonatal outcome. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial in 17 US centers enrolled pregnant adults aged 18 to 45 years with preexisting type 2 diabetes or diabetes diagnosed prior to 23 weeks' gestation between April 2019 and November 2021. Each participant was treated with insulin and was assigned to add either metformin or placebo. Follow-up was completed in May 2022. INTERVENTION: Metformin 1000 mg or placebo orally twice per day from enrollment (11 weeks -<23 weeks) through delivery. MAIN OUTCOME AND MEASURES: The primary outcome was a composite of neonatal complications including perinatal death, preterm birth, large or small for gestational age, and hyperbilirubinemia requiring phototherapy. Prespecified secondary outcomes included maternal hypoglycemia and neonatal fat mass at birth, and prespecified subgroup analyses by maternal body mass index less than 30 vs 30 or greater and those with preexisting vs diabetes early in pregnancy. RESULTS: Of the 831 participants randomized, 794 took at least 1 dose of the study agent and were included in the primary analysis (397 in the placebo group and 397 in the metformin group). Participants' mean (SD) age was 32.9 (5.6) years; 234 (29%) were Black, and 412 (52%) were Hispanic. The composite adverse neonatal outcome occurred in 280 (71%) of the metformin group and in 292 (74%) of the placebo group (adjusted odds ratio, 0.86 [95% CI 0.63-1.19]). The most commonly occurring events in the primary outcome in both groups were preterm birth, neonatal hypoglycemia, and delivery of a large-for-gestational-age infant. The study was halted at 75% accrual for futility in detecting a significant difference in the primary outcome. Prespecified secondary outcomes and subgroup analyses were similar between groups. Of individual components of the composite adverse neonatal outcome, metformin-exposed neonates had lower odds to be large for gestational age (adjusted odds ratio, 0.63 [95% CI, 0.46-0.86]) when compared with the placebo group. CONCLUSIONS AND RELEVANCE: Using metformin plus insulin to treat preexisting type 2 or gestational diabetes diagnosed early in pregnancy did not reduce a composite neonatal adverse outcome. The effect of reduction in odds of a large-for-gestational-age infant observed after adding metformin to insulin warrants further investigation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02932475.
引用
- Boggess KA, Valint A, Refuerzo JS, et al. Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial. JAMA. 2023. PMID: 38085312. doi:10.1001/jama.2023.22949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。